Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3762 Target Snapshot

Voltage-dependent L-type calcium channel subunit alpha-1C · SINGLE PROTEIN · Rattus norvegicus

1,227Compounds
156Assays
24Approved Drugs
200.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P22002. Use UniProt P22002 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P22002 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent L-type calcium channel subunit alpha-1C as ChEMBL target CHEMBL3762, mapped to UniProt P22002. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Voltage-dependent L-type calcium channel subunit alpha-1C
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL3762
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P22002
Voltage-dependent L-type calcium channel subunit alpha-1C
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-dependent L-type calcium channel subunit alpha-1C is the right protein anchor across sources, using UniProt P22002 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVoltage-dependent L-type calcium channel subunit alpha-1C
UniProt AccessionP22002
Component TypeProtein
Sequence Length2169 aa

Voltage-dependent L-type calcium channel subunit alpha-1C

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Voltage-dependent L-type calcium channel subunit alpha-1C, mapped to UniProt P22002. Sequence length is 2169 aa.

Mapped IDP22002
Review nameVoltage-dependent L-type calcium channel subunit alpha-1C
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

24
Approved
2
Phase III
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50148.0
KI48.0
EC504.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL193 8.85 IC50 1.42 Approved
CHEMBL1491 8.7 Ki 2.0 Approved
CHEMBL104455 8.67 Ki 2.16 Preclinical
CHEMBL3350845 8.67 Ki 2.15 Preclinical
CHEMBL3350842 8.62 Ki 2.4 Preclinical
CHEMBL193 8.46 Ki 3.5 Approved
CHEMBL325811 8.25 Ki 5.63 Preclinical
CHEMBL3350227 8.1 Ki 8.0 Preclinical
CHEMBL24675 8.08 Ki 8.3 Preclinical
CHEMBL104082 8.06 Ki 8.69 Preclinical
Distribution

pChEMBL Value Distribution

38
5.0
23
5.5
13
6.0
17
6.5
19
7.0
15
7.5
6
8.0
5
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CANNABIDIOL
CHEMBL190461
Approved 2018
AMLODIPINE
CHEMBL1491
Approved 1992
TERFENADINE
CHEMBL17157
Approved 1985
DILTIAZEM
CHEMBL23
Approved 1982
NIFEDIPINE
CHEMBL193
Approved 1981
VERAPAMIL
CHEMBL6966
Approved 1981
Assay Landscape

Assay Landscape

156
Total Assays
84
Tested Compounds
3
Assay Types
Binding — 78 assays, 68 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 46 2 7.4
tissue-based format 9 19 6.9
assay format 8 1 5.5
cell membrane format 7 16 7.2
cell-based format 7 30 6.2
protein format 1 0
Functional — 77 assays, 84 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 64 51 5.3
tissue-based format 8 26 6.2
assay format 5 7 7.1
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
tissue-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine